

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-60. Canceled

61. (Previously Presented) An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:299, wherein said polypeptide is expressed in breast tumor tissue.

62. (Currently Amended) An isolated polypeptide that is at least 90% identical to the amino acid sequence of SEQ ID NO:299, wherein said polypeptide is expressed in breast tumor tissue.

63. (Currently Amended) An isolated polypeptide according to claim 62, wherein said polypeptide is at least 95% identical to the amino acid sequence of SEQ ID NO:299.

64. (Previously Presented) An isolated polypeptide comprising the amino acid sequence encoded by the polynucleotide sequence of SEQ ID NO:292.

65. (Previously Presented) An isolated polypeptide comprising the amino acid sequence of SEQ ID NO:299.

66. (Currently Amended) An isolated polypeptide according to any one of claims 61-65, in combination with a physiologically acceptable carrier.

67. (Currently Amended) An isolated polypeptide according to any one of claims 61-65, in combination with an immunostimulant.

68. (Previously Presented) An isolated polypeptide according to claim 67, wherein said immunostimulant is an adjuvant.

69. (Previously Presented) An isolated polypeptide according to claim 67, wherein said immunostimulant induces a predominantly Type I response.